Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Amyris to Perform

Oppenheimer Downgrades Amyris to Perform

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

Analyst Ratings

Analyst Expectations for JPMorgan Chase’s Future

By Benzinga Insights

August 1, 8:00 AM

Analysts have provided the following ratings for JPMorgan Chase (NYSE:JPM) within the last quarter: Bullish Somewhat Bullish Indifferent…

JPM

Tech Titans Tumble: ‘Magnificent Seven’ Shed $250 Billion in Market Cap On 2024 Day One

By Piero Cingari

January 2, 5:34 PM

The Magnificent Seven's market cap plunged by $250 billion in the first trading session of the year, led by Apple Inc.'s 4% drop and a sell call from Barclays analyst Tim Long.

AAPL

Could Walmart’s AI Leap Be A Game-Changer in the Retail Landscape?

By Anusuya Lahiri

October 5, 8:27 AM

Walmart Inc (NYSE: WMT) will likely disrupt the customer shopping experience by integrating generative AI tools. These innovations enhance every phase of the customer's journey, from product discovery to purchase.

AMZN

What’s Going On With Travere Therapeutics Stock?

By Erica Kollmann

December 5, 1:02 PM

Travere Therapeutics, Inc. (NASDAQ: TVTX) shares are trading higher Tuesday.

TVTX

Oppenheimer Downgrades Amyris to Perform

Related Posts

Analyst Expectations for JPMorgan Chase’s Future

Tech Titans Tumble: ‘Magnificent Seven’ Shed $250 Billion in Market Cap On 2024 Day One

Could Walmart’s AI Leap Be A Game-Changer in the Retail Landscape?

What’s Going On With Travere Therapeutics Stock?